NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Current Deferred Revenue for 6 consecutive years, with $305552.3 the latest figure, recorded in Q4 2023.

• In Q4 2023, Current Deferred Revenue fell 74.96% year-over-year to $305552.3; the TTM figure through Dec 2023 stood at $305552.3 (down 74.96% YoY), while the FY2023 annual figure was $600000.0, down 99.95% from the prior year.
• Current Deferred Revenue retreated to $305552.3 in Q4 2023 per NBP's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $8.2 million in Q2 2022 and bottomed at $305552.3 in Q4 2023.
• Historically, Current Deferred Revenue has averaged $1.7 million across 5 years, with a median of $1.1 million in 2020.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 1061.47% — and 2023, when it plunged 82.24%.
• NovaBridge Biosciences' Current Deferred Revenue stood at $556172.6 in 2019, then surged by 103.72% to $1.1 million in 2020, then tumbled by 37.69% to $706000.0 in 2021, then surged by 72.81% to $1.2 million in 2022, then slumped by 74.96% to $305552.3 in 2023.
• Business Quant data shows NBP's Current Deferred Revenue at $305552.3 in Q4 2023, $1.5 million in Q2 2023, and $1.2 million in Q4 2022.